FISH analysis in addition to G-band karyotyping: utility in evaluation of myelodysplastic syndromes?

Abstract:

:Cytogenetic analysis provides important diagnostic and prognostic information for patients with myelodysplastic syndromes (MDS). Prior studies, mostly comprised of small sample sizes, have reported conflicting results while evaluating the usefulness of FISH in addition to G-band karyotyping in MDS. In the current study, the utility of performing a tailored FISH panel, in addition to G-band karyotyping was evaluated in a series of 110 MDS patients diagnosed at our institute. Using our FISH panel, clonal cytogenetic abnormalities were detected in 3/8 (38%) of MDS cases with karyotype failure and in 5/54 (9%) cases with normal G-band karyotypes, all the latter had intermediate or high grade MDS. Of the cases with abnormal G-band karyotypes, 6/48 (13%) showed discrepancies between FISH and G-band results, however, FISH analysis only lead to reassignment of karyotypic abnormalities to different chromosomes, MDS cytogenetic risk stratification was not altered. Our findings suggest that FISH testing is informative only in MDS cases with karyotype failure and intermediate-high grade MDS cases with normal G-band karyotype and has limited utility in cases that have normal G-band karyotypes and morphologic features of low grade MDS or in cases with abnormal G-band karyotypes.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Yang W,Stotler B,Sevilla DW,Emmons FN,Murty VV,Alobeid B,Bhagat G

doi

10.1016/j.leukres.2009.09.013

subject

Has Abstract

pub_date

2010-04-01 00:00:00

pages

420-5

issue

4

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(09)00473-1

journal_volume

34

pub_type

杂志文章
  • Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.

    abstract::Forty patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) preceded by MDS were treated with intensive induction and consolidation chemotherapy in a prospective multicenter pilot study. They were given two cycles of cytarabine 100 mg/m with 12-h intervals on days 1-7 and idarubicin 12...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/s0145-2126(96)00116-6

    authors: Ruutu T,Hänninen A,Järventie G,Koistinen P,Koivunen E,Kätkä K,Nousiainen T,Oksanen K,Pelliniemi TT,Remes K,Timonen T,Volin L,Elonen E

    更新日期:1997-02-01 00:00:00

  • Susceptibility of mantle cell lymphomas to reovirus oncolysis.

    abstract::Mantle cell lymphoma (MCL) an incurable B-cell, non-Hodgkin lymphoma (NHL) urgently requires new treatments. We assessed reovirus mediated oncolysis in a panel of human MCL cell lines. In vitro, we found the cytopathic effect of reovirus infection ranged from high to very limited and correlated with levels of Ras acti...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.05.020

    authors: Alain T,Muzik H,Otsuka S,Chan S,Magliocco T,Diaz R,Forsyth PA,Morris D,Bebb G

    更新日期:2010-01-01 00:00:00

  • Socioeconomic status and event free survival in pediatric acute lymphoblastic leukemia: a population-based cohort study.

    abstract::The impact of socioeconomic status (SES) upon childhood cancer outcomes has not been extensively examined. Our objective was to determine the association between SES and event-free survival (EFS) among children with acute lymphoblastic leukemia (ALL) diagnosed in Ontario, Canada from 1995-2011 (N=1541) using Cox propo...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/j.leukres.2014.08.017

    authors: Gupta S,Sutradhar R,Guttmann A,Sung L,Pole JD

    更新日期:2014-12-01 00:00:00

  • Detection of fos oncogene products by monoclonal antibody FO-120 in lymphoproliferative disorders.

    abstract::We investigated the expression of fos oncogene proteins in lymphoproliferative disorders, using a monoclonal antibody (FO-120) that was prepared against a synthetic oligopeptide of fos protein (amino acid sequence from 127 to 152). Although peripheral blood leukocytes were rarely positive for FO-120, they were transie...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(89)90010-6

    authors: Kanaitsuka T,Namba Y,Zu YL,Ishii K,Ashihara T,Hanaoka M,Suchi T

    更新日期:1989-01-01 00:00:00

  • Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia.

    abstract::Ectopic expression of LMO2 occurs in approximately 45% of T-lineage acute lymphoblastic leukemias (T-ALL), sometimes in association with chromosomal translocations. Recently, a lymphoproliferative disorder developed in two participants in a gene therapy trial due to LMO2 activation via integration of the retroviral ve...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2004.05.013

    authors: Hammond SM,Crable SC,Anderson KP

    更新日期:2005-01-01 00:00:00

  • Inherited pericentric inversion of chromosome 16 in chronic phase of chronic myeloid leukaemia.

    abstract::The simultaneous occurrence of two specific acquired chromosomal abnormalities in chronic or acute leukaemias is rare. Inherited chromosomal abnormalities are also rare events in the general population. In chronic myeloid leukaemia (CML), characterised by the t(9;22)(q34;q11), the inv(16)(p13q22) has been described as...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.06.003

    authors: Silva PM,Lourenço GJ,Bognone RA,Delamain MT,Pinto-Junior W,Lima CS

    更新日期:2006-01-01 00:00:00

  • Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.

    abstract::Allogeneic stem cell transplantation is considered to be a curative treatment modality in patients with chronic myelogenous leukemia. However patients are at risk for relapse years after transplantation. Currently we present two patients who relapsed 16 and 24 years after allogeneic bone marrow transplantation, respec...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.03.010

    authors: Sekhri A,Liu D,Rasul M,Ahmed N,Ahmed T,Seiter K

    更新日期:2009-09-01 00:00:00

  • KN-62 analogues as potent differentiating agents of HL-60 cells.

    abstract::KN-62, an inhibitor of the calmodulin-dependent protein kinases (CaMKs), enhances the terminal differentiation of retinoic acid sensitive human myeloid leukemia cell lines. In an effort to identify additional CaMK inhibitors that exhibit more potent activity in triggering leukemia cell differentiation, we synthesized ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.07.022

    authors: Schuler AD,Si J,Mueller L,Simon JA,Collins SJ

    更新日期:2007-05-01 00:00:00

  • Real-world costs of chronic lymphocytic leukaemia in the Netherlands.

    abstract::We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chronic lymphocytic leukaemia in daily practice. In our observational study 160 patient charts were reviewed repeatedly to assess the treatment strategies from diagnosis till the study end. Ninety-seven patients (61%) recei...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2013.10.029

    authors: Holtzer-Goor KM,Bouwmans-Frijters CA,Schaafsma MR,de Weerdt O,Joosten P,Posthuma EF,Wittebol S,Huijgens PC,Mattijssen EJ,Vreugdenhil G,Visser H,Peters WG,Erjavec Z,Wijermans PW,Daenen SM,van der Hem KG,van Oers MH,Groot

    更新日期:2014-01-01 00:00:00

  • Induction of mixed allogeneic chimerism for leukemia.

    abstract::Hybrid (C56BL/6 x DBA) (BDF1; H-2b/H-2d) mice bearing the P815 leukemia (H-2d) were grafted with a (CBA x C57BL/6)F1 (CBF1; H-2k/H-2b) cell suspension, comprising bone marrow cells (BMC; 25 x 10(6)/mouse) and spleen cells (SC; 55 x 10(6)/mouse) on day-4, then treated with cyclophosphamide (200 mg/kg) on day-2 and fina...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(97)00011-8

    authors: Seledtsov VI,Seledtsova GV,Avdeev EV,Samarin DM,Kozlov VA

    更新日期:1997-10-01 00:00:00

  • Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies.

    abstract::Bi-specific anti-CD33 x anti-CD64 antibodies (BsAb) mediated more potent and longer-lasting inhibition of proliferation of human leukemia cell lines and primary acute myeloid leukemia (AML) samples compared to mono-specific anti-CD33 mAb. There were no differences between these two antibodies in cellular internalizati...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2003.12.001

    authors: Balaian L,Ball ED

    更新日期:2004-08-01 00:00:00

  • Analysis of chromosome 12p deletion in plasma cell dyscrasias.

    abstract::The prognostic relevance of 12p deletion is controversial in multiple myeloma (MM) and the status of 12p deletion is unknown in other plasma cell disorders. We investigated 12p deletion in 88 patients with MM, 19 patients with monoclonal gammopathy of undetermined significance (MGUS), and 17 patients with plasma cell ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2011.07.030

    authors: Jiang N,Qi C,Yu L,Ning Y,An G,Qiu L,Chang H

    更新日期:2012-01-01 00:00:00

  • Challenges in the use of NG2 antigen as a marker to predict MLL rearrangements in multi-center studies.

    abstract::Rearrangements in MLL (MLL-r) are common within very young children with leukemia and affect the prognosis and treatment. Previous studies have suggested the use of the NG2 molecule as a marker for MLL-r but these studies were performed using a small number of infants. We analyzed 148 patients (all less than 24 months...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2011.03.006

    authors: Emerenciano M,Renaud G,Sant'Ana M,Barbieri C,Passetti F,Pombo-de-Oliveira MS,Brazilian Collaborative Study Group of Infant Acute Leukemia.

    更新日期:2011-08-01 00:00:00

  • Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk³⁴⁸) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML).

    abstract::We investigated Syk as a potential marker of CML progression. We observed a significant over-expression of Syk mRNA and constitutive phosphorylation of Syk Y348 in blast cells from six AP or BP-CML, but not in 15 CML in chronic phase. We could follow in vivo the recurrence of pSyk(348) throughout blast cell escape, de...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2014.11.014

    authors: Bourgne C,Janel A,Berger J,Rapatel C,Tournilhac O,Hermet E,Guerci A,Lioret F,Briançon A,Bamdad M,Boiret-Dupré N,Berger MG

    更新日期:2015-03-01 00:00:00

  • Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients.

    abstract::The aim of this study was to evaluate effect of c-KIT mutations on RUNX1/RUNX1T1 fusion transcript expression in patients with t(8;21)-positive AML. Fifty patients diagnosed with t(8;21)-positive AML for recent 10 years were enrolled. Patients with c-KIT mutations tended to achieve a greater than 3-log reduction in RU...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2013.02.010

    authors: Park SH,Chi HS,Cho YU,Jang S,Park CJ

    更新日期:2013-07-01 00:00:00

  • A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.

    abstract::Despite initial remissions, most patients with Ph chromosome positive (Ph(+)) acute leukemia (AL) become refractory to tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib. This study was designed to determine if targeting the interleukin-3 receptor (IL-3R) with a diphtheria toxin fusion protein (DT(388)IL...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.12.008

    authors: Kim HP,Frankel AE,Hogge DE

    更新日期:2010-08-01 00:00:00

  • Expression of the testis-specific gene, TSGA10, in Iranian patients with acute lymphoblastic leukemia (ALL).

    abstract::Testis-specific gene antigen (TSGA10) is expressed in fetus, testis and frequently in human solid cancers and acute leukemias, making it a candidate for immunotherapy and for detection of minimal residual disease (MRD). This gene is considered as a member of cancer-testis (CT) genes. We previously demonstrated TSGA10 ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.11.012

    authors: Mobasheri MB,Modarressi MH,Shabani M,Asgarian H,Sharifian RA,Vossough P,Shokri F

    更新日期:2006-07-01 00:00:00

  • Higher T-cell imbalance and growth factor receptor expression in B-cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS).

    abstract::The surface marker phenotype of lymphocytes derived from 12 patients with B-CLL was compared to that of lymphocytes from 10 patients with an other monoclonal but clinical benign form of B-cell proliferative disorder termed monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS). A panel of well character...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(89)90028-3

    authors: Garcia C,Rosén A,Kimby E,Aguilar-Santelises M,Jondal M,Bjorkholm M,Holm G,Mellstedt H

    更新日期:1989-01-01 00:00:00

  • The expression and function of E3 ligase SIAH2 in acute T lymphoblastic leukemia.

    abstract:INTRODUCTION:The seven in absentia homolog 2 (SIAH2) protein plays a significant role in human cancer by regulating hypoxia-inducible factor-a (HIF-1α); however, its role in T-cell acute lymphoblastic leukemia (T-ALL) is less clear. METHODS:Immunofluorescence evaluation of SIAH2 protein expression and location were co...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2016.01.013

    authors: Chen H,Wang N,Yang G,Guo Y,Shen Y,Wang X,Zhang P,Xu Y

    更新日期:2016-03-01 00:00:00

  • Enhancement of leukemia rejection by mice successfully treated for L1210 leukemia due to low dose compared to high dose VP-16.

    abstract::We have earlier shown that VP-16 combined with Cyclosporin A (CsA) produces tumor specific immunity to L1210 leukemia in BDF/1 mice [Slater LM, Sweet P, Stupecky M, Reynolds JT. Cyclosporin A/VP-16 produced immunity to L1210 leukemia: the participation of cytotoxic CD(8) T-lymphocytes, Clin Immunol Immunopathol 1995;7...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(01)00105-9

    authors: Slater LM,Stupecky M,Sweet P,Osann KE

    更新日期:2002-02-01 00:00:00

  • Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemias.

    abstract::Increased DNA damage and alteration of the DNA damage response (DDR) are critical features of genetic instability presumably implicated in pathogenesis of myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML). We used immunofluorescence staining of γH2AX and 53BP1 for analyzing DNA double-strand breaks (DS...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2017.03.011

    authors: Popp HD,Naumann N,Brendel S,Henzler T,Weiss C,Hofmann WK,Fabarius A

    更新日期:2017-06-01 00:00:00

  • Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.

    abstract::We hypothesized that the high early death rate (EDR) due to bleeding in acute promyelocytic leukemia (APL) is in part attributable to delays in all- trans retinoic acid (ATRA). We conducted a retrospective analysis of the timing of ATRA administration. 204 consecutive patients with newly diagnosed APL between 1992 and...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2013.05.007

    authors: Altman JK,Rademaker A,Cull E,Weitner BB,Ofran Y,Rosenblat TL,Haidau A,Park JH,Ram SL,Orsini JM Jr,Sandhu S,Catchatourian R,Trifilio SM,Adel NG,Frankfurt O,Stein EM,Mallios G,Deblasio T,Jurcic JG,Nimer S,Peterson L

    更新日期:2013-09-01 00:00:00

  • Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. II. Action on human hematopoietic stem cells.

    abstract::Osteogenic growth peptide (OGP) is a peptide exerting regulatory effects on the bone and on bone marrow. The carboxy-terminal pentapeptide (OGP10-14) is the biologically active portion of OGP. We evaluated OGP10-14 hematopoietic activity performing colony-forming tests on human stem cells derived by bone marrow, perip...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(02)00008-5

    authors: Fazzi R,Galimberti S,Testi R,Pacini S,Trasciatti S,Rosini S,Petrini M

    更新日期:2002-09-01 00:00:00

  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.

    abstract::There is a significant need for improved therapeutics in older patients with acute leukemia. Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation an...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2020.106385

    authors: Goldberg AD,Atallah E,Rizzieri D,Walter RB,Chung KY,Spira A,Stock W,Tallman MS,Cruz HG,Boni J,Havenith KEG,Chao G,Feingold JM,Wuerthner J,Solh M

    更新日期:2020-08-01 00:00:00

  • Erythropoietin.

    abstract::The remarkable capacity of the bone marrow to compensate for blood loss and for reduced atmospheric oxygen tension has been found to be mediated by a renal hormone, named erythropoietin. It is produced by peritubular interstitial cells in response to renal hypoxia, but molecular engineering has permitted large scale p...

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/0145-2126(90)90094-p

    authors: Erslev AJ

    更新日期:1990-01-01 00:00:00

  • YM155 suppresses cell proliferation and induces cell death in human adult T-cell leukemia/lymphoma cells.

    abstract::Adult T-cell leukemia (ATL) is an aggressive malignancy of peripheral T cells infected with human T-cell leukemia virus type 1 (HTLV-1). The prognosis of patients with aggressive ATL remains poor because ATL cells acquire resistance to conventional cytotoxic agents. Therefore, development of novel agents is urgently n...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2015.10.012

    authors: Sasaki R,Ito S,Asahi M,Ishida Y

    更新日期:2015-12-01 00:00:00

  • Proliferation in liquid culture of megakaryocytes from the blood of patients with primary myelofibrosis and other myeloproliferative disorders.

    abstract::Using a short term liquid system we have shown that blood from some patients with primary myelofibrosis (PMF) and chronic granulocytic leukaemia (CGL) in megakaryoblastic transformation (CGL-Mk) gives rise to large numbers of progenitor cells committed to the megakaryocyte (Mk) lineage. As assessed by indirect immunof...

    journal_title:Leukemia research

    pub_type: 历史文章,杂志文章

    doi:10.1016/0145-2126(85)90108-0

    authors: Hibbin JA,Matutes E,Goldman JM

    更新日期:1985-01-01 00:00:00

  • Pycnogenol induces differentiation and apoptosis in human promyeloid leukemia HL-60 cells.

    abstract::Pycnogenol, rich of many phytochemicals of medical value, is a commercialized nutrient supplement extracted from the bark of European coastal pine. In this study, we investigated the anti-tumor effects of Pycnogenol on HL-60, U937 and K562 human leukemia cell lines. We found that Pycnogenol inhibited cell proliferatio...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2004.10.006

    authors: Huang WW,Yang JS,Lin CF,Ho WJ,Lee MR

    更新日期:2005-06-01 00:00:00

  • Bryostatin-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells.

    abstract::In this study we explored the effects of bryostatin-5 on the clonogenic response of normal bone marrow mononuclear (BM) cells and HL60 myeloid leukemia cells. Leukemic HL60 colony formation was strongly inhibited by bryostatin-5 depending on dose and schedule. An inhibitory effect on HL60 colony formation was readily ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(94)00118-t

    authors: van der Hem KG,Dräger AM,Odding JH,Langenhuijsen MM,Huijgens PC

    更新日期:1995-01-01 00:00:00

  • Unusual course of an acute lymphoblastic leukemia case with i(9q) as a sole cytogenetic abnormality.

    abstract::Chromosomal changes are necessary in determining the classification, prognosis and using the appropriate therapeutic regimen in acute leukemia. Isochromosomes are uncommon chromosome aberations in childhood acute lymphoblastic leukemia (ALL) and the effect of i(9q) is not well established. We present an 8-year-old mal...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.02.018

    authors: Cogulu O,Karapinar DY,Karaca E,Aydinok Y,Ozkinay F

    更新日期:2006-11-01 00:00:00